Founder and Chief Executive Officer, Insilico Medicine. Background in biomedicine and computer technology. Recognized by Deep Knowledge Analytics in 2019 as one of the top 100 artificial intelligence (AI) leaders in drug discovery and advanced healthcare globally and selected as one of Clarivate's Global Highly Cited Scientists for 2022. Founded Insilico in 2014. In 2016, pioneered the application of key technologies in generative adversarial networks (GANs) and reinforcement learning (RL) to drug discovery. Prior to Insilico, worked in senior roles at ATI Technologies, NeuroGNeuroinformatics, Biogerontology Research Foundation. Has published over 200 peer- reviewed research papers and 3 books. Member, Advisory Board, Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, npj Aging. Co-chairs the Annual Aging Research, Drug Discovery and AI Forum. Adjunct Professor of AI, Buck Institute for Research on Aging.
En la industria farmacéutica, las empresas invierten varias décadas, decenas de miles de millones de dólares e incontables horas experimentando con animales y seres humanos para intentar ...
In the pharmaceutical industry, companies spend several decades, tens of billions of dollars, and countless hours experimenting on animals and humans trying to prove a hypothesis that a c...
